These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24351500)

  • 21. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.
    Woodrell C; Weiss J; Branch A; Gardenier D; Krauskopf K; Kil N; Paredes H; Bichoupan K; Sigel K
    J Addict Med; 2015; 9(5):405-10. PubMed ID: 26291545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
    Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
    Gurusamy KS; Tsochatzis E; Davidson BR; Burroughs AK
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006573. PubMed ID: 21154370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of treatment for hepatitis C virus infection in the primary care setting.
    Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ
    Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):1003-9. PubMed ID: 25051216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
    Siebert U; Sroczynski G; ;
    Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients.
    Mustafa M; Hussain S; Qureshi S; Malik SA; Kazmi AR; Naeem M
    BMC Gastroenterol; 2012 Aug; 12():117. PubMed ID: 22925702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
    An J; Qiao J; Ni W
    Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):772-3. PubMed ID: 25558497
    [No Abstract]   [Full Text] [Related]  

  • 31. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Aguilar Reina J
    Rev Esp Enferm Dig; 2009 Oct; 101(10):665-70. PubMed ID: 19899934
    [No Abstract]   [Full Text] [Related]  

  • 32. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical features and treatment outcome of chronic hepatitis C with pegylated interferon and ribavirin in routine care.
    Tan SS; Adlin Nadia Z
    Med J Malaysia; 2017 Jun; 72(3):165-174. PubMed ID: 28733564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
    Jung YK; Kim JH
    Clin Mol Hepatol; 2013 Mar; 19(1):26-8. PubMed ID: 23593606
    [No Abstract]   [Full Text] [Related]  

  • 35. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
    Fabrizi F; Dixit V; Messa P
    J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Goals of treatment, indication, and treatment for chronic hepatitis C].
    Paik SW
    Korean J Gastroenterol; 2008 Jun; 51(6):368-71. PubMed ID: 18604138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.
    Huckans M; Mitchell A; Ruimy S; Loftis J; Hauser P
    Schizophr Bull; 2010 Jan; 36(1):165-72. PubMed ID: 18562341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
    Cornberg M; Wedemeyer H; Manns MP
    Curr Gastroenterol Rep; 2002 Feb; 4(1):23-30. PubMed ID: 11825538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.